Avalo Therapeutics posts corporate deck spotlighting IL-1β inhibitor pipeline for hidradenitis suppurativa
Reuters2026/08/06 11:26- Avalo outlined an IL-1β inhibitor strategy for immune-mediated inflammatory diseases, led by abdakibart in moderate-to-severe hidradenitis suppurativa.
- Phase 2 LOTUS met its primary endpoint, with 42.5% HiSCR75 at week 16 versus 25.6% for placebo across dose arms.
- HiSCR50 reached 61.7% across dose arms versus 40.7% for placebo; abdakibart was described as well tolerated with no neutropenia signal.
- Phase 3 initiation targeted for 1H 2027; AVTX-010 expected to advance to IND in 1H 2027.
- May 2026 financing totaled $431.3 million; cash runway expected to fund operations into 2029, including anticipated Phase 3 topline data.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen consolidates near August highs vs USD as hawkish BoJ, Fed bets clash
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Crypto prices
More
